An aerosolized vaccine for measles was developed in Mexico and has been used on more than 44 million children since 1980. Aerosolized vaccines have the advantages of being able to be administered by people without clinical training and do not cause injectionassociated infections. Despite these advantages, data about efficacy of the aerosolized vaccines against measles compared to subcutaneous injection of the vaccine have been inconsistent. Because of this, a large randomized controlled study was conducted with children inIndia.

The primary outcome was an immune response to measles measured 9191 days after the treatments. Among the 785785 children receiving the subcutaneous injection, 743743 developed an immune response, while among the 775775 children receiving the aerosolized vaccine, 662662 developed an immuneresponse.

Nicola Low et al., "A randomized, controlled trial of an aerosolized vaccine against measles," New England Journal of Medicine, 372 (2015), pp.1519-1529.

Macmillan Learning

Compute the proportion of subjects experiencing the primary outcome for both the aerosol and injection groups. Give your answers to four decimalplaces.

aerosolized=^aerosolized=

injection=^injection=

Give a 95%95% confidence interval for the difference between the proportion of the children in the aerosol and injection groups who experienced the primary outcome. Give your answers to four decimalplaces.

lowerbound:

upperbound: